← Back to Clinical Trials
Recruiting NCT07642180

NCT07642180 Combined Effects of Pelvic Floor Retraining and Hypopressive Exercises in Uterine Prolapse Outcomes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07642180
Status Recruiting
Phase
Sponsor Riphah International University
Condition Uterine Prolapse
Study Type INTERVENTIONAL
Enrollment 32 participants
Start Date 2025-04-02
Primary Completion 2026-06-02

Eligibility & Interventions

Sex Female only
Min Age 30 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Functional Movement Retraining + Hypopressive ExercisesPelvic Floor Functional Movement Retraining

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 32 participants in total. It began in 2025-04-02 with a primary completion date of 2026-06-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

One common pelvic floor condition, particularly in postpartum or later life, is uterine prolapse. It is caused by weak pelvic floor muscles and connective tissues and often presents with pain, urinary incontinence, and reduced quality of life. Although pelvic floor muscle training (PFMT) is commonly used, newer methods such as Hypopressive Exercises (HE) and Pelvic Floor Functional Movement Retraining (PFFMR) offer promising approaches. HE focuses on posture and breathing strategies to reduce intra-abdominal pressure, while PFFMR retrains pelvic stability and function through integrated movement patterns. This study aims to evaluate the combined effects of HE and PFFMR on pain, urogynecological symptoms, and quality of life in women with uterine prolapse, compared to single interventions. This randomized clinical trial will include 32 women aged 30-60 years with stage I-II uterine prolapse at Ganga Ram Hospital, Lahore. Participants will undergo an 8-week program with supervised sessions three times per week. Outcomes will be assessed using the Pelvic Floor Bother Questionnaire (PFBQ), Numeric Pain Rating Scale (NPRS), and Prolapse Quality of Life Questionnaire (P-QoL), and analyzed using SPSS version 25.0.

Eligibility Criteria

Inclusion Criteria: * Females aged 30-60 years. * Diagnosed with stage I and II uterine prolapse. * women with ≥1 parity * women who have had a vaginal delivery Exclusion Criteria: * Recent pelvic surgery (\<6 months). * Pregnancy or postpartum within 6 months. * Neurological conditions affecting muscle control. * Participation in pelvic floor rehab in the past 6 months.

Contact & Investigator

Central Contact

Imran Amjad, PHD*

✉ imran.amjad@riphah.edu.pk

📞 03324390125

Principal Investigator

Zunaira Bilal

PRINCIPAL INVESTIGATOR

Riphah International University

Frequently Asked Questions

Who can join the NCT07642180 clinical trial?

This trial is open to female participants only, aged 30 Years or older, up to 60 Years, studying Uterine Prolapse. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07642180 currently recruiting?

Yes, NCT07642180 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.

Where is the NCT07642180 trial being conducted?

This trial is being conducted at Lahore, Pakistan.

Who is sponsoring the NCT07642180 clinical trial?

NCT07642180 is sponsored by Riphah International University. The principal investigator is Zunaira Bilal at Riphah International University. The trial plans to enroll 32 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology